Published in J Virol on October 01, 2001
Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. J Virol (2002) 5.20
Functional surfaces of the human immunodeficiency virus type 1 capsid protein. J Virol (2003) 4.47
Evidence for direct involvement of the capsid protein in HIV infection of nondividing cells. PLoS Pathog (2007) 2.75
Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation. J Virol (2004) 2.65
Characterization of a putative alpha-helix across the capsid-SP1 boundary that is critical for the multimerization of human immunodeficiency virus type 1 gag. J Virol (2002) 1.96
Small-molecule inhibition of human immunodeficiency virus type 1 infection by virus capsid destabilization. J Virol (2010) 1.92
Structural requirements for recognition of the human immunodeficiency virus type 1 core during host restriction in owl monkey cells. J Virol (2005) 1.79
3-O-(3',3'-dimethysuccinyl) betulinic acid inhibits maturation of the human immunodeficiency virus type 1 Gag precursor assembled in vitro. J Virol (2006) 1.58
Kinetic analysis of the role of intersubunit interactions in human immunodeficiency virus type 1 capsid protein assembly in vitro. J Virol (2002) 1.55
Nucleocapsid protein function in early infection processes. Virus Res (2008) 1.53
Novel approaches to inhibiting HIV-1 replication. Antiviral Res (2009) 1.48
HIV-1 Gag processing intermediates trans-dominantly interfere with HIV-1 infectivity. J Biol Chem (2009) 1.47
Role of HIV-1 nucleocapsid protein in HIV-1 reverse transcription. RNA Biol (2010) 1.35
Mutation of dileucine-like motifs in the human immunodeficiency virus type 1 capsid disrupts virus assembly, gag-gag interactions, gag-membrane binding, and virion maturation. J Virol (2006) 1.35
Flexibility in HIV-1 assembly subunits: solution structure of the monomeric C-terminal domain of the capsid protein. Biophys J (2007) 1.29
A mutation in alpha helix 3 of CA renders human immunodeficiency virus type 1 cyclosporin A resistant and dependent: rescue by a second-site substitution in a distal region of CA. J Virol (2007) 1.28
Human immunodeficiency virus type 1 N-terminal capsid mutants containing cores with abnormally high levels of capsid protein and virtually no reverse transcriptase. J Virol (2003) 1.24
Virus particle core defects caused by mutations in the human immunodeficiency virus capsid N-terminal domain. J Virol (2005) 1.24
RSV capsid polymorphism correlates with polymerization efficiency and envelope glycoprotein content: implications that nucleation controls morphogenesis. J Mol Biol (2007) 1.19
Cell factors stimulate human immunodeficiency virus type 1 reverse transcription in vitro. J Virol (2007) 1.14
Virus maturation as a new HIV-1 therapeutic target. Expert Opin Ther Targets (2009) 1.13
HIV-1 uncoating: connection to nuclear entry and regulation by host proteins. Virology (2014) 1.12
Effects of blocking individual maturation cleavages in murine leukemia virus gag. J Virol (2004) 1.12
Mutational analysis of the N-terminal domain of Moloney murine leukemia virus capsid protein. J Virol (2007) 1.12
ATPgammaS disrupts human immunodeficiency virus type 1 virion core integrity. J Virol (2005) 1.08
Role of human immunodeficiency virus type 1 integrase in uncoating of the viral core. J Virol (2010) 1.07
VSV-G pseudotyping rescues HIV-1 CA mutations that impair core assembly or stability. Retrovirology (2008) 1.03
Effect of polypurine tract (PPT) mutations on human immunodeficiency virus type 1 replication: a virus with a completely randomized PPT retains low infectivity. J Virol (2005) 1.01
Fundamental differences between the nucleic acid chaperone activities of HIV-1 nucleocapsid protein and Gag or Gag-derived proteins: biological implications. Virology (2010) 1.01
Correct capsid assembly mediated by a conserved YXXLGL motif in prototype foamy virus Gag is essential for infectivity and reverse transcription of the viral genome. J Virol (2007) 1.00
Critical role of conserved hydrophobic residues within the major homology region in mature retroviral capsid assembly. J Virol (2008) 1.00
Complementary Assays Reveal a Low Level of CA Associated with Viral Complexes in the Nuclei of HIV-1-Infected Cells. J Virol (2015) 1.00
A carboxy-terminally truncated human CPSF6 lacking residues encoded by exon 6 inhibits HIV-1 cDNA synthesis and promotes capsid disassembly. J Virol (2013) 0.99
The interdomain linker region of HIV-1 capsid protein is a critical determinant of proper core assembly and stability. Virology (2011) 0.99
Hydrogen bonding at a conserved threonine in lentivirus capsid is required for virus replication. J Virol (2003) 0.99
Identification of capsid mutations that alter the rate of HIV-1 uncoating in infected cells. J Virol (2014) 0.97
The role of amino-terminal sequences in cellular localization and antiviral activity of APOBEC3B. J Virol (2011) 0.94
Effects of Gag mutation and processing on retroviral dimeric RNA maturation. J Virol (2006) 0.94
Mutations in the thumb allow human immunodeficiency virus type 1 reverse transcriptase to be cleaved by protease in virions. J Virol (2009) 0.94
The dimerization domain of the HIV-1 capsid protein binds a capsid protein-derived peptide: a biophysical characterization. Protein Sci (2004) 0.92
Characterization of the invariable residue 51 mutations of human immunodeficiency virus type 1 capsid protein on in vitro CA assembly and infectivity. Retrovirology (2007) 0.92
New approaches for antiviral targeting of HIV assembly. J Mol Biol (2011) 0.92
PDZD8 is a novel Gag-interacting factor that promotes retroviral infection. J Virol (2010) 0.91
An extensive thermodynamic characterization of the dimerization domain of the HIV-1 capsid protein. Protein Sci (2005) 0.89
Compensatory substitutions in the HIV-1 capsid reduce the fitness cost associated with resistance to a capsid-targeting small-molecule inhibitor. J Virol (2014) 0.89
Capsid is an important determinant for functional complementation of murine leukemia virus and spleen necrosis virus Gag proteins. Virology (2006) 0.86
The cyclosporin A washout assay to detect HIV-1 uncoating in infected cells. Methods Mol Biol (2014) 0.86
Fitness costs of mutations at the HIV-1 capsid hexamerization interface. PLoS One (2013) 0.86
Safeguard against DNA sensing: the role of TREX1 in HIV-1 infection and autoimmune diseases. Front Microbiol (2014) 0.84
A small loop in the capsid protein of Moloney murine leukemia virus controls assembly of spherical cores. J Virol (2006) 0.82
Genetic Studies of the beta-hairpin loop of Rous sarcoma virus capsid protein. J Virol (2006) 0.81
Slower uncoating is associated with impaired replicative capability of simian-tropic HIV-1. PLoS One (2013) 0.81
Coarse-grained simulation reveals key features of HIV-1 capsid self-assembly. Nat Commun (2016) 0.80
Analysis of human T-cell leukemia virus type 1 particles by using cryo-electron tomography. J Virol (2014) 0.80
Viral precursor polyproteins: keys of regulation from replication to maturation. Curr Opin Virol (2013) 0.79
Effects of rapid antigen degradation and VEE glycoprotein specificity on immune responses induced by a VEE replicon vaccine. Virology (2007) 0.79
A second-site suppressor significantly improves the defective phenotype imposed by mutation of an aromatic residue in the N-terminal domain of the HIV-1 capsid protein. Virology (2006) 0.79
Potential role for CA-SP in nucleating retroviral capsid maturation. J Virol (2014) 0.78
The cellular factors Vps18 and Mon2 are required for efficient production of infectious HIV-1 particles. J Virol (2011) 0.77
Dominance effects of deleterious and beneficial mutations in a single gene of the RNA virus ϕ6. PLoS One (2014) 0.77
How SLX4 cuts through the mystery of HIV-1 Vpr-mediated cell cycle arrest. Retrovirology (2014) 0.77
Capsid proteins from human immunodeficiency virus type 1 and simian immunodeficiency virus SIVmac can coassemble into mature cores of infectious viruses. J Virol (2008) 0.77
Recovery of fitness of a live attenuated simian immunodeficiency virus through compensation in both the coding and non-coding regions of the viral genome. Retrovirology (2007) 0.77
Composite Sequence-Structure Stability Models as Screening Tools for Identifying Vulnerable Targets for HIV Drug and Vaccine Development. Viruses (2015) 0.77
Genetic footprinting of a retroviral Gag gene suggests an important role in virus replication. Proc Natl Acad Sci U S A (2003) 0.76
Contributions of Charged Residues in Structurally Dynamic Capsid Surface Loops to Rous Sarcoma Virus Assembly. J Virol (2016) 0.76
Inhibition of HIV-1 Maturation via Small-Molecule Targeting of the Amino-Terminal Domain in the Viral Capsid Protein. J Virol (2017) 0.75
Effect of internal cleavage site mutations in human immunodeficiency virus type 1 capsid protein on its structure and function. FEBS Open Bio (2016) 0.75
Forced Complementation between Subgenomic RNAs: Does Human Immunodeficiency Type 1 Virus Reverse Transcription Occur in Viral Core, Cytoplasm, or Early Endosome? J AIDS Immune Res (2015) 0.75
Cyclophilin A potentiates TRIM5α inhibition of HIV-1 nuclear import without promoting TRIM5α binding to the viral capsid. PLoS One (2017) 0.75
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol (1986) 37.70
Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol (1992) 12.89
Form, function, and use of retroviral gag proteins. AIDS (1991) 9.24
HIV-1 gag proteins: diverse functions in the virus life cycle. Virology (1998) 7.32
Specific incorporation of cyclophilin A into HIV-1 virions. Nature (1994) 7.13
p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease. J Virol (1995) 6.87
Functional association of cyclophilin A with HIV-1 virions. Nature (1994) 6.82
Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid. Cell (1996) 6.74
Assembly and analysis of conical models for the HIV-1 core. Science (1999) 6.35
Structure of the carboxyl-terminal dimerization domain of the HIV-1 capsid protein. Science (1997) 6.10
Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle. J Virol (1992) 5.78
Structure of the amino-terminal core domain of the HIV-1 capsid protein. Science (1996) 5.44
Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range. J Virol (1991) 4.74
Assembly and morphology of HIV: potential effect of structure on viral function. AIDS (1991) 4.73
Partial reverse transcripts in virions from human immunodeficiency and murine leukemia viruses. J Virol (1992) 4.72
Proteolytic refolding of the HIV-1 capsid protein amino-terminus facilitates viral core assembly. EMBO J (1998) 4.46
Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription. J Virol (1996) 4.15
Role of the basic domain of human immunodeficiency virus type 1 matrix in macrophage infection. J Virol (1995) 3.95
Crystal structure of dimeric HIV-1 capsid protein. Nat Struct Biol (1996) 3.93
Viral DNA carried by human immunodeficiency virus type 1 virions. J Virol (1992) 3.93
Nucleic-acid-chaperone activity of retroviral nucleocapsid proteins: significance for viral replication. Trends Biochem Sci (1998) 3.78
Maturation of dimeric viral RNA of Moloney murine leukemia virus. J Virol (1993) 3.78
Assembly, processing, and infectivity of human immunodeficiency virus type 1 gag mutants. J Virol (1993) 3.75
Characterization of human immunodeficiency virus type 1 dimeric RNA from wild-type and protease-defective virions. J Virol (1994) 3.54
Functional domains of the capsid protein of human immunodeficiency virus type 1. J Virol (1994) 3.47
Deficiency of 60 to 70S RNA in murine leukemia virus particles assembled in cells treated with actinomycin D. J Virol (1974) 3.37
Evidence for a functional interaction between the V1/V2 and C4 domains of human immunodeficiency virus type 1 envelope glycoprotein gp120. J Virol (1994) 3.07
A mutation in the human immunodeficiency virus type 1 transmembrane glycoprotein gp41 dominantly interferes with fusion and infectivity. Proc Natl Acad Sci U S A (1992) 3.01
A conformational switch controlling HIV-1 morphogenesis. EMBO J (2000) 2.86
Biochemical and structural analysis of isolated mature cores of human immunodeficiency virus type 1. J Virol (2000) 2.80
Enhanced expression of a glyceraldehyde-3-phosphate dehydrogenase gene in human lung cancers. Cancer Res (1987) 2.65
Association of Nef with the human immunodeficiency virus type 1 core. J Virol (1999) 2.62
Role of matrix in an early postentry step in the human immunodeficiency virus type 1 life cycle. J Virol (1998) 2.62
Linker insertion mutations in the human immunodeficiency virus type 1 gag gene: effects on virion particle assembly, release, and infectivity. J Virol (1995) 2.56
N-Terminal extension of human immunodeficiency virus capsid protein converts the in vitro assembly phenotype from tubular to spherical particles. J Virol (1998) 2.49
Role of Vif in human immunodeficiency virus type 1 reverse transcription. J Virol (1996) 2.35
The role of Gag in human immunodeficiency virus type 1 virion morphogenesis and early steps of the viral life cycle. J Virol (1996) 2.31
HIV-1 nucleocapsid protein induces "maturation" of dimeric retroviral RNA in vitro. Proc Natl Acad Sci U S A (1996) 2.30
Human immunodeficiency virus type 1 integrase protein promotes reverse transcription through specific interactions with the nucleoprotein reverse transcription complex. J Virol (1999) 2.16
Mass determination of rous sarcoma virus virions by scanning transmission electron microscopy. J Virol (1999) 2.15
In vitro synthesis of infectious DNA of murine leukaemia virus. Nature (1977) 2.06
Structural biology of HIV. J Mol Biol (1999) 2.03
Proline residues in the HIV-1 NH2-terminal capsid domain: structure determinants for proper core assembly and subsequent steps of early replication. Virology (2000) 1.77
Isolation of human immunodeficiency virus type 1 cores: retention of Vpr in the absence of p6(gag). J Virol (2000) 1.76
Second-site suppressors of Rous sarcoma virus Ca mutations: evidence for interdomain interactions. J Virol (2001) 1.55
Nascent human immunodeficiency virus type 1 reverse transcription occurs within an enveloped particle. J Virol (1995) 1.54
Amino acid substitutions in the CA protein of Moloney murine leukemia virus that block early events in infection. Virology (1996) 1.47
Viral DNA synthesis defects in assembly-competent Rous sarcoma virus CA mutants. J Virol (2001) 1.39
Reversion of a human immunodeficiency virus type 1 matrix mutation affecting Gag membrane binding, endogenous reverse transcriptase activity, and virus infectivity. J Virol (1999) 1.26
Cyclophilin A incorporation is not required for human immunodeficiency virus type 1 particle maturation and does not destabilize the mature capsid. Virology (1999) 1.13
Functional analysis of reverse transcription by a frameshift pol mutant of murine leukemia virus. Virology (1985) 0.92
Generation of HIV-1/HIV-2 cross-reactive peptide antisera by small sequence changes in HIV-1 reverse transcriptase and integrase immunizing peptides. J Biomed Sci (1998) 0.83
p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease. J Virol (1995) 6.87
'Vascular depression' hypothesis. Arch Gen Psychiatry (1997) 6.59
Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc Natl Acad Sci U S A (2001) 5.46
Support for and reported compliance with smoke-free restaurants and bars by smokers in four countries: findings from the International Tobacco Control (ITC) Four Country Survey. Tob Control (2006) 4.85
Prediction of acute left main coronary artery obstruction by 12-lead electrocardiography. ST segment elevation in lead aVR with less ST segment elevation in lead V(1). J Am Coll Cardiol (2001) 4.81
Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med (1996) 4.61
Death from paraquat in a child. Lancet (1968) 4.29
PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci U S A (2003) 4.03
Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet (1994) 4.03
Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis). Cytometry (1997) 3.90
Nucleic-acid-chaperone activity of retroviral nucleocapsid proteins: significance for viral replication. Trends Biochem Sci (1998) 3.78
Second-trimester abortion after vaginal termination of pregnancy. Lancet (1972) 3.55
A recombination hotspot responsible for two inherited peripheral neuropathies is located near a mariner transposon-like element. Nat Genet (1996) 3.45
Assembly of recombinant human immunodeficiency virus type 1 capsid protein in vitro. J Virol (1992) 3.44
Deficiency of 60 to 70S RNA in murine leukemia virus particles assembled in cells treated with actinomycin D. J Virol (1974) 3.37
Developmental regulation of zebrafish MyoD in wild-type, no tail and spadetail embryos. Development (1996) 3.30
Efficient promoter cassettes for enhanced expression of foreign genes in dicotyledonous and monocotyledonous plants. Plant Cell Physiol (1996) 3.30
Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest (1995) 3.19
Binding of human immunodeficiency virus type 1 Gag to membrane: role of the matrix amino terminus. J Virol (1999) 3.13
Growth of the fetal biparietal diameter during normal pregnancy. J Obstet Gynaecol Br Commonw (1971) 3.04
Infectivity of Moloney murine leukemia virus defective in late assembly events is restored by late assembly domains of other retroviruses. J Virol (2000) 2.98
Rapid detection of vancomycin-resistant enterococci. J Clin Microbiol (1994) 2.92
Is third trimester abortion justified? Br J Obstet Gynaecol (1995) 2.89
Role of the Gag matrix domain in targeting human immunodeficiency virus type 1 assembly. J Virol (2000) 2.85
Transvaginal three-dimensional ultrasound: accuracy of follicular volume measurements. Fertil Steril (1996) 2.72
Ultrasound-guided sampling of umbilical cord and placental blood to assess fetal wellbeing. Lancet (1986) 2.72
The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions. Proc Natl Acad Sci U S A (2000) 2.70
Role of matrix in an early postentry step in the human immunodeficiency virus type 1 life cycle. J Virol (1998) 2.62
Urine collection from disposable nappies. Lancet (1991) 2.61
Can health care quality indicators be transferred between countries? Qual Saf Health Care (2003) 2.58
Purification and characterization of the human interleukin-18 receptor. J Biol Chem (1997) 2.58
Arrest of preterm labour and prolongation of gestation with glyceryl trinitrate, a nitric oxide donor. Lancet (1994) 2.53
Doppler studies in the growth retarded fetus and prediction of neonatal necrotising enterocolitis, haemorrhage, and neonatal morbidity. Br Med J (Clin Res Ed) (1987) 2.50
Integration is required for productive infection of monocyte-derived macrophages by human immunodeficiency virus type 1. J Virol (1995) 2.43
Antithyroid drug-induced agranulocytosis. The usefulness of routine white blood cell count monitoring. Arch Intern Med (1990) 2.39
Dbl family proteins. Biochim Biophys Acta (1997) 2.36
An improved method of fetal cephalometry by ultrasound. J Obstet Gynaecol Br Commonw (1968) 2.33
Murine leukemia virus mutant with a frameshift in the reverse transcriptase coding region: implications for pol gene structure. J Virol (1984) 2.32
Team structure, team climate and the quality of care in primary care: an observational study. Qual Saf Health Care (2003) 2.31
HIV-1 nucleocapsid protein induces "maturation" of dimeric retroviral RNA in vitro. Proc Natl Acad Sci U S A (1996) 2.30
Genetic evidence for an interaction between human immunodeficiency virus type 1 matrix and alpha-helix 2 of the gp41 cytoplasmic tail. J Virol (2000) 2.27
Echocardiographic and anatomical correlates in the fetus. Br Heart J (1980) 2.27
Physical examination tests of the shoulder: a systematic review with meta-analysis of individual tests. Br J Sports Med (2007) 2.25
Activation of the ERK/MAPK pathway by an isoform of rap1GAP associated with G alpha(i) Nature (1999) 2.23
Canadian-French, German and UK versions of the Child Health Questionnaire: methodology and preliminary item scaling results. Qual Life Res (1998) 2.22
The cumulative embryo score: a predictive embryo scoring technique to select the optimal number of embryos to transfer in an in-vitro fertilization and embryo transfer programme. Hum Reprod (1992) 2.21
Ultrasound screening for familial ovarian cancer. Gynecol Oncol (1991) 2.19
Ultrasound measurement of the fetal head to abdomen circumference ratio in the assessment of growth retardation. Br J Obstet Gynaecol (1977) 2.18
New doppler technique for assessing uteroplacental blood flow. Lancet (1983) 2.15
Synthesis of murine leukemia virus proteins associated with virions assembled in actinomycin D-treated cells: evidence for persistence of viral messenger RNA. Proc Natl Acad Sci U S A (1976) 2.14
Current topic: in vivo investigation of the placental circulations by Doppler echography. Placenta (1995) 2.13
Factors affecting visualization of postmenopausal ovaries: descriptive study from the multicenter United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Ultrasound Obstet Gynecol (2013) 2.11
Renal oncocytoma: a clinicopathologic study of 70 cases. Am J Surg Pathol (1997) 2.10
Analysis of arbovirus ribonucleic acid forms by polyacrylamide gel electrophoresis. J Virol (1971) 2.10
Quality indicators for primary care mental health services. Qual Saf Health Care (2003) 2.10
Leukocytes infiltrate the myometrium during human parturition: further evidence that labour is an inflammatory process. Hum Reprod (1999) 2.09
A molecular redox switch on p21(ras). Structural basis for the nitric oxide-p21(ras) interaction. J Biol Chem (1997) 2.08
Relationship between human immunodeficiency virus type 1 Gag multimerization and membrane binding. J Virol (2000) 2.07
The role of envelope glycoprotein processing in murine leukemia virus infection. J Virol (1987) 2.06
West Nile virus isolates from mosquitoes in New York and New Jersey, 1999. Emerg Infect Dis (2001) 2.05
Normal fetal cardiac anatomy--a basis for the echocardiographic detection of abnormalities. Prenat Diagn (1981) 2.05
Selective packaging of host tRNA's by murine leukemia virus particles does not require genomic RNA. J Virol (1979) 2.04
Nonresponse bias and early versus all responders in mail and telephone surveys. Am J Epidemiol (1984) 2.04
Cumulative conception and livebirth rates after in-vitro fertilisation. Lancet (1992) 2.01
Diffusion-weighted single-shot echoplanar MR imaging for liver disease. AJR Am J Roentgenol (1999) 2.00
Identification and synthesis of a recognition signal for the attachment of glycosaminoglycans to proteins. Proc Natl Acad Sci U S A (1987) 2.00
Diagnosis and treatment of early cervical pregnancy: a review and a report of two cases treated conservatively. Ultrasound Obstet Gynecol (1996) 1.99
Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging. BMJ (1993) 1.98
Transvaginal colour flow imaging: a possible new screening technique for ovarian cancer. BMJ (1989) 1.96
How women view postepisiotomy pain. Br Med J (Clin Res Ed) (1982) 1.94
Translational suppression in retroviral gene expression. Adv Virus Res (1992) 1.93
The prediction of fetal maturity by ultrasonic measurement of the biparietal diameter. J Obstet Gynaecol Br Commonw (1969) 1.90
Mutant of B-tropic murine leukemia virus synthesizing an altered polymerase molecule. J Virol (1979) 1.90
Substitution at codon 269 (glutamine --> proline) of the leptin receptor (OB-R) cDNA is the only mutation found in the Zucker fatty (fa/fa) rat. Biochem Biophys Res Commun (1996) 1.89
Sex-specific antenatal reference growth charts for uncomplicated singleton pregnancies at 15-40 weeks of gestation. Ultrasound Obstet Gynecol (2004) 1.89
Ultrasonographically detectable markers of fetal chromosomal abnormalities. Lancet (1992) 1.88
Zinc finger structures in the human immunodeficiency virus type 1 nucleocapsid protein facilitate efficient minus- and plus-strand transfer. J Virol (2000) 1.88
Follow-up study of small-for-dates babies. Br Med J (1976) 1.86
Association of SPINK5 gene polymorphisms with atopic dermatitis in the Japanese population. Br J Dermatol (2003) 1.86
Membrane-associated replication complex in arbovirus infection. J Virol (1972) 1.83
Human immunodeficiency virus type 1 nucleocapsid protein reduces reverse transcriptase pausing at a secondary structure near the murine leukemia virus polypurine tract. J Virol (1996) 1.83
Early cancer of the stomach. World J Surg (1979) 1.82
Localization of DNA binding activity of HIV-1 integrase to the C-terminal half of the protein. AIDS Res Hum Retroviruses (1992) 1.82
The present place of routine ultrasound screening. Clin Obstet Gynaecol (1983) 1.82
Real-time ultrasonography for determination of ovarian morphology and volume. A possible early screening test for ovarian cancer? Lancet (1982) 1.82
Prediction of pre-eclampsia by abnormal uterine Doppler ultrasound and modification by aspirin. Br J Obstet Gynaecol (1996) 1.79
HIV-1 infection of non-dividing cells. Nature (1994) 1.79
Oestrogen therapy and the menopausal syndrome. Clin Obstet Gynaecol (1977) 1.77
The prenatal diagnosis of fetal structural anomalies by ultrasound. Clin Obstet Gynaecol (1983) 1.77
Effect of diagnostic ultrasound on maternal and fetal chromosomes. Lancet (1971) 1.76
Functional characteristics of Peyer's patch lymphoid cells. I. Induction of humoral antibody and cell-mediated allograft reactions. J Exp Med (1974) 1.76
Pathway of chymotrypsin evolution suggested by the structure of the FMN-binding protein from Desulfovibrio vulgaris (Miyazaki F) Nat Struct Biol (1997) 1.75
Intracellular Ca2+-dependent protease (calpain) and its high-molecular-weight endogenous inhibitor (calpastatin). Adv Enzyme Regul (1980) 1.74
Sampling pure fetal blood by fetoscopy in second trimester of pregnancy. Br Med J (1978) 1.73
Epidermal growth factor receptor overexpression and genetic aberrations in metastatic squamous-cell carcinoma of the skin. Dermatology (2001) 1.72
Doppler investigation of uteroplacental blood flow resistance in the second trimester: a screening study for pre-eclampsia and intrauterine growth retardation. Br J Obstet Gynaecol (1991) 1.70
Oestrogens, arterial status, and postmenopausal women. Lancet (1990) 1.70
Maternal serum-alpha-fetoprotein levels and prenatal diagnosis of neural-tube defects. Lancet (1974) 1.69